ME02211B - Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja - Google Patents

Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja

Info

Publication number
ME02211B
ME02211B MEP-2015-150A MEP15015A ME02211B ME 02211 B ME02211 B ME 02211B ME P15015 A MEP15015 A ME P15015A ME 02211 B ME02211 B ME 02211B
Authority
ME
Montenegro
Prior art keywords
mmol
compound
reference compound
stirred
mixture
Prior art date
Application number
MEP-2015-150A
Other languages
English (en)
Unknown language (me)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02211(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of ME02211B publication Critical patent/ME02211B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MEP-2015-150A 2009-12-31 2010-12-30 Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja ME02211B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
EP13198224.1A EP2719699B1 (en) 2009-12-31 2010-12-30 Certain triazolopyrazines, compositions thereof and methods of use therefor

Publications (1)

Publication Number Publication Date
ME02211B true ME02211B (me) 2016-02-20

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-150A ME02211B (me) 2009-12-31 2010-12-30 Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja

Country Status (38)

Country Link
US (9) US8987269B2 (enExample)
EP (5) EP2519524A4 (enExample)
JP (5) JP5337313B2 (enExample)
KR (3) KR101771299B1 (enExample)
CN (3) CN106432225B (enExample)
AU (2) AU2010338712B2 (enExample)
BR (1) BR112012016129B1 (enExample)
CA (1) CA2785749C (enExample)
CL (1) CL2012001752A1 (enExample)
CO (1) CO6612235A2 (enExample)
CU (1) CU24167B1 (enExample)
CY (2) CY1118250T1 (enExample)
DK (3) DK3795573T3 (enExample)
DO (1) DOP2012000188A (enExample)
EA (2) EA030141B1 (enExample)
EC (1) ECSP12012011A (enExample)
ES (4) ES2927146T3 (enExample)
GT (1) GT201200220A (enExample)
HR (3) HRP20221090T1 (enExample)
HU (3) HUE025504T2 (enExample)
IL (2) IL220433B (enExample)
LT (1) LT3795573T (enExample)
ME (1) ME02211B (enExample)
MX (2) MX336996B (enExample)
MY (1) MY179933A (enExample)
NI (1) NI201200118A (enExample)
NZ (1) NZ601128A (enExample)
PE (3) PE20211094A1 (enExample)
PH (1) PH12012501355A1 (enExample)
PL (3) PL2719699T3 (enExample)
PT (3) PT3511330T (enExample)
RS (3) RS63612B1 (enExample)
SG (1) SG181781A1 (enExample)
SI (2) SI3511330T1 (enExample)
SM (3) SMT202000693T1 (enExample)
UA (1) UA107822C2 (enExample)
WO (1) WO2011079804A1 (enExample)
ZA (1) ZA201205730B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2719699T3 (pl) * 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
MX359888B (es) * 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
CA2901269C (en) 2013-03-06 2022-01-18 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
RU2643361C2 (ru) * 2013-09-30 2018-02-01 Кореа Рисёч Инститьют Оф Кемикал Текнолоджи Новые производные триазолопиразина и их применение
AU2014370186A1 (en) * 2013-12-26 2016-07-14 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10344035B2 (en) * 2015-12-31 2019-07-09 Shanghai Phaarmaceuticals Holding Co., Ltd. Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
EP3589628B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
CN112839945A (zh) 2018-09-06 2021-05-25 艾其林医药公司 补体因子d抑制剂的形态形式
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
IL281283B2 (en) * 2018-09-11 2024-01-01 Astrazeneca Ab Improved method for the production of 3-[(1S)-1-imidazolo[1,2-A]pyridine-6-ylethyl]-5-(1-methylpyrazol-1-YL]triazolo[4,5-B]pyrazine and polymeric forms His
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN113454080B (zh) * 2018-10-30 2025-10-28 修复治疗公司 化合物、药物组合物和制备化合物的方法以及其使用方法
EA202191541A1 (ru) 2018-12-14 2022-01-21 Бета Фарма, Инк. ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
EP3941462A4 (en) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
PH12022550156A1 (en) * 2019-07-22 2023-05-08 Repare Therapeutics Inc Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
US20250197403A1 (en) * 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
JP2023543990A (ja) * 2020-09-28 2023-10-19 コデクシス， インコーポレイテッド キラルアミンを合成するための操作された生体触媒および方法
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
CN119136800A (zh) * 2022-04-20 2024-12-13 恩格莱尔治疗公司 Gabaa受体调节剂盐、颗粒及其用途
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
AU2023312919A1 (en) * 2022-07-29 2025-03-06 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
CN120835885A (zh) * 2023-01-04 2025-10-24 缆图药品公司 Cdk2抑制剂
GB202300923D0 (en) 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002516326A (ja) * 1998-05-26 2002-06-04 メルク エンド カムパニー インコーポレーテッド イミダゾピリジン系トロンビン阻害薬
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
PL1853602T3 (pl) * 2005-02-16 2010-11-30 Astrazeneca Ab Związki chemiczne
JP5144532B2 (ja) * 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
ES2612377T3 (es) * 2005-12-21 2017-05-16 Janssen Pharmaceutica N.V. Triazolopiridazinas como moduladores de tirosina cinasas
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
MX2009002842A (es) 2006-09-18 2009-05-27 Vertex Pharma Inhibidores heterociclicos de c-met y usos de los mismos.
US8507489B2 (en) 2006-10-23 2013-08-13 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
EA016527B1 (ru) * 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2683398A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
US8673970B2 (en) * 2008-02-21 2014-03-18 Sequoia Pharmaceuticals, Inc. HIV protease inhibitor and cytochrome p450 inhibitor combinations
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
ES2376404T3 (es) 2008-05-22 2012-03-13 Amgen Inc. Heterociclos como inhibidores de proteínas cinasas.
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP5781510B2 (ja) * 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
KR20120089463A (ko) * 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
PL2719699T3 (pl) * 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
PL3795573T3 (pl) 2022-11-21
AU2015203480B2 (en) 2017-10-26
MX2012007756A (es) 2012-11-06
KR101434766B1 (ko) 2014-08-26
US10946014B2 (en) 2021-03-16
RS63612B1 (sr) 2022-10-31
EP2966075A1 (en) 2016-01-13
EP2966075B1 (en) 2019-02-27
AU2015203480A1 (en) 2015-07-16
PT3795573T (pt) 2022-09-15
GT201200220A (es) 2014-12-22
HRP20221090T1 (hr) 2022-11-25
US9956218B2 (en) 2018-05-01
DK3511330T3 (da) 2020-12-21
KR20120125261A (ko) 2012-11-14
JP2013209418A (ja) 2013-10-10
NZ601128A (en) 2014-12-24
IL239997A0 (en) 2015-08-31
US20180263977A1 (en) 2018-09-20
SI3511330T1 (sl) 2021-01-29
AU2010338712B2 (en) 2015-04-02
EA030141B1 (ru) 2018-06-29
EP3795573B1 (en) 2022-07-06
MX386852B (es) 2025-03-19
JP2013516393A (ja) 2013-05-13
PT2719699E (pt) 2015-09-30
HRP20150952T1 (hr) 2015-10-09
IL239997A (en) 2017-11-30
CY1123777T1 (el) 2022-03-24
HUE059696T2 (hu) 2022-12-28
ES2546635T3 (es) 2015-09-25
CO6612235A2 (es) 2013-02-01
US10512645B2 (en) 2019-12-24
LT3795573T (lt) 2022-11-10
CN106117248B (zh) 2019-01-22
PL3511330T3 (pl) 2021-04-19
BR112012016129B1 (pt) 2020-11-03
EP2719699A1 (en) 2014-04-16
EA201691461A1 (ru) 2017-01-30
PL2719699T3 (pl) 2016-01-29
JP2019108345A (ja) 2019-07-04
CN106117248A (zh) 2016-11-16
US20250099462A1 (en) 2025-03-27
US20120245178A1 (en) 2012-09-27
EP2719699B1 (en) 2015-07-08
PE20160588A1 (es) 2016-07-09
US20210154192A1 (en) 2021-05-27
RS54217B1 (sr) 2015-12-31
SG181781A1 (en) 2012-07-30
SMT202200371T1 (it) 2022-11-18
CN102906092B (zh) 2016-08-03
US20170027934A1 (en) 2017-02-02
ES2726152T3 (es) 2019-10-02
JP2018009004A (ja) 2018-01-18
CA2785749C (en) 2017-11-28
CA2785749A1 (en) 2011-07-07
PH12012501355A1 (en) 2012-12-17
RS61281B1 (sr) 2021-02-26
US20200179377A1 (en) 2020-06-11
CY1118250T1 (el) 2017-06-28
EP2519524A4 (en) 2013-07-03
DK2719699T3 (en) 2015-08-24
MX336996B (es) 2016-02-09
SMT202000693T1 (it) 2021-01-05
JP2016155848A (ja) 2016-09-01
PT3511330T (pt) 2020-12-24
IL220433B (en) 2018-01-31
DK3795573T3 (da) 2022-09-19
CN106432225A (zh) 2017-02-22
CL2012001752A1 (es) 2013-01-25
HUE052828T2 (hu) 2021-05-28
EA025466B1 (ru) 2016-12-30
CN106432225B (zh) 2019-02-19
JP5337313B2 (ja) 2013-11-06
MY179933A (en) 2020-11-19
US11896592B2 (en) 2024-02-13
AU2010338712A1 (en) 2012-07-12
CU24167B1 (es) 2016-03-31
US8507487B2 (en) 2013-08-13
SI2719699T1 (sl) 2015-12-31
CU20120101A7 (es) 2012-10-15
UA107822C2 (xx) 2015-02-25
EP2519524A1 (en) 2012-11-07
KR101905350B1 (ko) 2018-11-30
HUE025504T2 (en) 2016-02-29
HK1194071A1 (en) 2014-10-10
HRP20202017T1 (hr) 2021-02-19
US20120264739A1 (en) 2012-10-18
US20150368271A1 (en) 2015-12-24
ES2927146T3 (es) 2022-11-02
JP6647434B2 (ja) 2020-02-14
EP3511330A1 (en) 2019-07-17
JP6194046B2 (ja) 2017-09-06
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
SMT201500213B (it) 2015-10-30
US20240139182A1 (en) 2024-05-02
KR20170098324A (ko) 2017-08-29
CN102906092A (zh) 2013-01-30
BR112012016129A2 (pt) 2016-05-31
EA201200951A1 (ru) 2013-09-30
US8987269B2 (en) 2015-03-24
KR20140059307A (ko) 2014-05-15
WO2011079804A1 (en) 2011-07-07
EP3511330B1 (en) 2020-09-30
ECSP12012011A (es) 2012-10-30
KR101771299B1 (ko) 2017-08-24
PE20130375A1 (es) 2013-04-10
EP3795573A1 (en) 2021-03-24
ZA201205730B (en) 2016-01-27
JP6486999B2 (ja) 2019-03-20
HK1216880A1 (en) 2016-12-09

Similar Documents

Publication Publication Date Title
ME02211B (me) Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
HK40049874B (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK40049874A (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK40011539B (en) Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors
HK40011539A (en) Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors
HK1194071B (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK1216880B (en) Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.